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HD Physiology Project—Japanese efforts to promote
multilevel integrative systems biology and physiome research
Kazuharu Furutani1,2, Kunichika Tsumoto1 and Yoshihisa Kurachi1,2 for HD physiology project investigators
The HD Physiology Project is a Japanese research consortium that aimed to develop methods and a computational platform in
which physiological and pathological information can be described in high-level definitions across multiple scales of time and size.
During the 5 years of this project, an appropriate software platform for multilevel functional simulation was developed and a whole-
heart model including pharmacokinetics for the assessment of the proarrhythmic risk of drugs was developed. In this article, we
outline the description and scientific strategy of this project and present the achievements and influence on multilevel integrative
systems biology and physiome research.
npj Systems Biology and Applications  (2017) 3:1 ; doi:10.1038/s41540-016-0001-0
INTRODUCTION
Systems biology is the field of study that considers the complexity
of biological systems among different scales of biological
organization, from the molecular to the cellular, tissue, organ,
organism, and even societal and ecosystem levels.1 Systems
biology aims for a more profound understanding of biological
processes and is characterized by the development of experiment-
based mathematical modeling and its application, combined with
experimental empirical studies. Therefore, systems biological
approaches rely heavily on experimental and quantitative data,
as well as modeling techniques spanning multiple spatial and
temporal scales and also different levels of biological organization.
The term “physiome,” from “physio-” (life) and “-ome” (as a
whole), comprehensively and quantitatively describes the physio-
logical dynamics of the functional behaviors of organisms,
including humans, and is built upon information and structure
(i.e., the genome, proteome, and morphome). Global efforts have
led to the establishment of various national projects on the
physiome, such as the German virtual liver network (http://www.
virtual-liver.de/). Another physiome project is the Wellcome
Trust Heart Physiome Project (Physiome Project, http://
physiomeproject.org/), which is part of the wider International
Union of Physiological sciences (IUPS) physiome project.2,3 This
IUPS physiome project aims to completely describe the heart,
including its anatomy; molecular, cellular, and organ mechanics;
electrophysiology; electro-mechanical coupling; and metabolic
processes in health and disease states. In addition, there are
several scientific societies, for example, the Cardiac Physiome
Society (http://cardiacphysiome.org/) that was created to respond
to the researcher’s need and hold an academic meeting to discuss
the current research topics and to exchange ideas cross-nationally
in the field of the integrative systems biology.
The massive amount of existing biological data obtained in a
variety of contexts are subdivided and fragmented. This unwieldy
amount of information makes it difficult to see the big picture of
functional behaviors in biological systems. Life science researchers
are confronting this issue. We should develop a framework for
organizing knowledge, specifically that obtained from different
levels, as well as methodology to study the dynamic behavior of
complex biological systems.
THE HD PHYSIOLOGY PROJECT
The HD Physiology Project (http://hd-physiology.jp/) whose name
represents high-definition, human disease, and hierarchical-
designed physiology, was a major Japanese project organizing a
consortium of laboratories renowned for their expertise in heart
physiology and circulatory molecular dynamics, thus encompass-
ing the historical core of systems biology research in Japan. The
project, with Japanese Ministry of Education, Culture, Sports,
Science and Technology (MEXT) support (around ¥300,000,000 per
year) from 2010 to 2016, tackled one of the major challenges in
multilevel integrative systems biology and physiome. This
interdisciplinary project focused on biological relativity between
different organism levels and explored the systems theory for
function emergence owing to the interactions among compo-
nents. The consortium formed a strong network that shared
expertise, tools, and methods, consequently enhancing synergy.
Furthermore, to understand basic concepts of life, novel
methodologies were required to integrate parts across multiple
levels of organisms and new infrastructure was required for
multilevel integrative systems biology and physiome research.
During the 5 years of this project, a software platform for
multilevel functional simulation with hierarchical-designed models
was developed and a whole-heart model that included a
pharmacokinetics model enabling assessment of the proarrhyth-
mic risk of drugs was attempted. Furthermore, an integrative and
holistic approach was introduced in order to reveal physiological
and pathophysiological mechanisms. The ultimate goal was to
identify key signaling molecules as novel drug targets
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for therapeutic intervention and/or as diagnostic biomarkers.
Moreover, the consortium attempted to provide technical and
theoretical frameworks for the HD Physiology Project and to lay
the foundation for “predictive medicine.”
DESCRIPTION AND SCIENTIFIC STRATEGY OF THE HD
PHYSIOLOGY PROJECT
In order to achieve its objectives, the 5-year program had to
address several organizational challenges arising from the
integration of multiple disciplines including molecular and cellular
biology, mathematics, physics, computer science, tissue engineer-
ing, and clinical imaging. The program encompassed about 40
sub-projects and involved approximately 250 scientists including
about 50 PIs/full professor and 150 junior faculties throughout
Japan (Table 1). This organization was planned by the leading
scientists to respond to the Japanese researcher’s need and was
approved by the grants reviewing committee in 2010. Scientists
involved in the planning had served as a dedicated core team of
project managers after the launch. They held the general meeting
Table 1 HD Physiology Project member list
HD Physiology Project
Axis Sub-project leader Affiliation Primal research area
Axis 01 Yoshihisa Kurachi Osaka University Physiome and systems biology (cardiac system) PL, CM
Hiroaki Kitano Okinawa Institute of Science and Technology Graduate University Systems biology (software, tools) PM, CM
Akira Amano Ritsumeikan University Computational physiology (cardiovascular system) CM
Kengo Kinoshita Tohoku University Molecular dynamics simulation CM
Yoshiyuki Hari Osaka University Organic chemistry CM
Kazuhiro Aoki Kyoto University Molecular imaging
Yuji Imaizumi Nagoya City University Molecular biology
Akira Funahashi Keio University Computational technology
Kenichi Hagihara Osaka University Parallel computation
Hideki Oka Tokai University Structural biomechanics (tissue/organ)
Axis 02 Ryuji Inoue Fukuoka University Physiology (ion channel, remodeling) PM, CM
Naomasa Makita Nagasaki University Cardiology (gene, arrhythmias) CM
Yoshihiro Ishikawa Yokohama City University Medical biology (G-protein signal transduction) CM
Haruo Honjo Nagoya University Biophysics (cardiac conduction system) CM
Kazuo Nakazawa National Cerebral and Cardiovascular Center Biomedical engineering (large scale heart simulation) CM
Kyoichi Ono Akita University Physiology (cardiac autorhythmicity)
Junko Kurokawa Tokyo Medical and Dental University Pharmacology (sex and gender aspects in arrhythmia)
Tomohiro Numata Kyoto University Physiology (ion channel)
Daiju Yamazaki Kyoto University Toxicology (Ca2+ signal)
Nagomi Kurebayashi Juntendo University Pharmacology (Ca2+ signal)
Satoshi Kurihara The Jikei University School of Medicine Physiology (muscle contraction)
Susumu Minamisawa The Jikei University School of Medicine Tissue engineering (Blood vessel)
Satomi Kita Fukuoka University Pharmacology (transporter)
Koichi Nakajo National Institute for Physiological Sciences Physiology (ion channel)
Takashi Aiba National Cerebral and Cardiovascular Center Clinician (gene, arrhythmias)
Haruo Ogawa University of Tokyo Structural biology (pump, transporter)
Hideki Ito Shiga University of Medical Science Clinician (gene, arrhythmias)
Ayako Takeuchi Fukui University Physiology (Ca2+ signal)
Tetsuo Shioi Kyoto University Cardiology (metabolic activity)
Yoichiro Kusakari The Jikei University School of Medicine Cardiology (heart failure)
Yasutaka Kurata Kanazawa Medical University Cardiology (triggered activities, bifurcation theory)
Motohiko Sato Aichi Medical University Biochemistry (G-protein signal transduction)
Axis 03 Hiroshi Suzuki University of Tokyo Hospital Systems pharmacology and toxicology PM, CM
Fumiyoshi Yamashita Kyoto University Clinical pharmacology PM, CM
Yasushi Okuno Kyoto University Bioinformatics (drug discovery) CM
Hiroyuki Kagechika Tokyo Medical and Dental University Chemical biology (transcriptional factors, retinoids) CM
Sumio Ohtsuki Tohoku University Drug transport, targeted proteomics CM
Hiroyuki Kusuhara University of Tokyo Molecular pharmacokinetics CM
Toshiya Katsura Kyoto University Molecular pharmacokinetics
Yasuo Yoshioka Osaka University Drug delivery system
Shushi Nagamori Osaka University Biochemistry (proteomics, transporter)
Yuichiro Fujiwara Osaka University Physiology and structural biology (ion channel)
Sawako Tatsumi Tokushima University Nutrition science (Inorganic phosphate homeostasis)
Fumiaki Nin Niigata University Physiology (inner ear function)
Kazuo Matsubara Kyoto University Clinical pharmacology
Shigehiro Ohdo Kyushu University Pharmacotherapy (circadian rhythm)
Takeshi Hiyama National Institute for Basic Biology Neuroscience (body-fluid homeostasis)
PL project leader, PM project manager, CM core member
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twice a year to get all members together so that they had grasped
the overall as well as individual situation. Then, as needed, they
gave the members adequate advice, introduced other members
who could help to solve the problem, and created the task force
team to work on the issue. For example, they created a specialized
task force team for the issues about model repository and huge
computation of hierarchical designed physiology models. They
also held the international symposium on this research three
times to provide an opportunity for Japanese researchers inside
and outside the project to discuss the current research topics and
to exchange ideas cross-nationally in the field of integrative
systems biology. As such, this project may provide insights into
the challenges of managing large and complex biological science
programs to ensure the delivery of ambitious objectives. Thus, our
experience provides a blueprint for other major flagship programs.
As illustrated in Fig. 1, the HD Physiology Project was organized
in three primary research axes, with the motivation described
later.
The first-axis, “Research and development of a software
platform for integrative multilevel systems biology,” aimed to
develop a better software platform for multilevel modeling and
simulation in systems biology, as well as to provide novel
technologies for accelerating calculations and for use in biological
experiments such as molecular compounds and probes.
The second-axis, entitled “Multilevel systems biology of cardiac
electrophysiological activity,” performed integrative research
on cardiac action potential and excitation propagation, which
underlie the heart’s function. This group was tasked with
understanding the robustness of electrical activity in the heart
on the basis of experimental studies from the molecular, cellular,
tissue, and organ levels, as well as from the perspective of heart
disease (e.g., arrhythmias).
The third-axis, entitled “Multilevel systems biology of small
molecular dynamics in circulation,” investigated the systems that
are homeostatically controlled by multiple organs. This group
started with pharmacokinetics and investigated the crucial
mechanisms underlying absorption, distribution, metabolism,
and excretion (ADME) systems. In this project, we conducted
physiologically based pharmacokinetic (PBPK) modeling for
predicting the ADME of synthetic or natural chemical substances
and hypothesis testing about the unknown mechanism under-
lying ADME, for example, lower-than-expected oral bioavailability.
The first axis was entrusted with a mission to provide new
methodologies for studying multilevel biological phenomena that
would benefit the rest of the consortium, as well as the fields of
systems biology, physiology, pharmacology, and medicine. Testing
the new methodological approaches in an iterative manner
necessitated specific and explicit physiological issues with
quantitative experimental verifications. Therefore, the second
and third-axes were specialized to investigate cardiology and
pharmacokinetics. The several important issues in cardiology arise
from vertical integration in the single organ, i.e., heart, while those
in pharmacokinetics arise from horizontal integration in the
multiple organs. By adopting such different technical approaches
and sharing the results, each axis expanded its own interests to
other physiological and pathological issues toward the shared
goal of quantitative theoretical and experimental investigation.
Indeed, exchanges of materials such as specially synthesized
chemical compounds, genes, model animals/cells, biological
structural data, and physiological hierarchy markup language
(PHML) models and techniques, including building/simulation of
physiological models, quantitative experimental techniques, and
mathematical analyses with the software tools, as well as formal
collaboration, occurred across several groups within the network
of the consortium. A large number of researchers of this project
Fig. 1 The HD Physiology Project framework research platform for multilevel systems biology, cardiome, and ADME/PK is being developed to
understand basic concepts of life and general mechanisms of robustness and regulation of biological networks that hold true for different
types of physiological issues
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have contributed to construct the flagship model that integrates
the knowledge about electrocardiology and pharmacokinetics on
the platform in order to guide the development of software
framework, which further promotes the researches in the 2nd and
third-axes. By promoting the research cycle, we expected to
identify general mechanisms of robustness and regulation of
biological networks that hold true for different types of
physiological issues.
RESEARCH ACHIEVEMENTS
Research and development of a software platform for integrative
multilevel systems biology (first-axis)
When the project was started, information on the subcellular and
cellular levels could be expressed by the model descriptive
language, systems biology markup language (SBML), which
became the de facto standard of the field of systems biology.4
Accordingly, mathematical models described in SBML enabled the
calculation of the dynamic behaviors of complex biomolecular
networks and pathways by using CellDesigner software.5,6 Next, a
descriptive language that can handle physiological information
from multiple levels (including the tissue, organ, and organism
levels) was required. Therefore, we developed a new XML-based
descriptive language format called PHML to model multilevel
physiological systems. In PHML, each of the elements constructing
a model is called a module.7–9 Hence, a model is represented as an
aggregate of modules. Structural and functional relationships
among the modules are defined by edges. Each module is
quantitatively characterized by several physical quantities that
represent dynamical variables, constants, and time-dependent
parameters. Morphological data and time series data can be
assigned to physical quantities as well. Definitions of the dynamics
or functions of physical quantities must be explicitly described by
mathematical equations such as algebraic equations and ordinary
differential equations (ODEs) that can include stochastic terms.
Hence, when we try to describe conformational changes of, for
example, tissues or body parts mathematically, such dynamical
motions can be described in PHML. Partial differential equations
(PDEs) are also available, but only with limited use, as a function to
involve PDEs is still under development. Moreover, we developed
PhysioDesigner, which is a platform on which users can build
mathematical models of multilevel physiological systems with a
graphical user interface, and Flint, which is a simulator developed
concomitantly with PhysioDesigner (Fig. 2)8,10 (Physiome.jp, http://
physiome.jp/). PhysioDesigner users can also develop mathema-
tical models with high freedom to integrate other models of
organs, tissues, and physiological functions, as PhysioDesigner is a
versatile platform for physiome and integrative multilevel systems
biology.
There have been pioneering efforts to develop modeling
standards, such as SBML (The SBML.org, http://sbml.org/) for
modeling mainly subcellular biochemical phenomena and CellML
(http://physiomeproject.org/software/cellml)11 for physiological
level modeling. PHML was developed to implement a unique
scheme representing state-transition variables that take discrete
states, such as close/open states of ionic channels, and to
construct large-scale models based on template and instance
modules. Moreover, collaborative functions with other descriptive
Fig. 2 Information flow with a focus on PhysioDesigne. This illustration is reproduced and reprinted with permission from the author and
from the website Physiome.jp (http://physiome.jp/)
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languages were paid careful attention in PHML. PHML has a partial
compatibility with CellML, i.e., a model written in CellML can be
converted into PHML, and a model written using a part of PHML
elements can be exported as a CellML model by PhysioDesigner.
Besides, a module of PHML can import a whole SBML model,
which is a unique feature of PHML to develop a multilevel model
of physiological systems by hybridizing two different descriptive
languages.
PhysioDesigner Version 1.0 α was launched in January 2012,
and the latest version (1.5) was launched on 30 June 2016.
PhysioDesigner has been downloaded approximately 1600 times
in 50 countries from the project website, Physiome.jp (http://
physiome.jp/). In addition, PhysioVisualizer and PHPlotter, which
visualize the results of computer simulations, were implemented,
and various databases, which is opened to the public, were built
as a PH database (http://physiome.jp/phdb/index.html).
Although a large number of software programs for the arts and
sciences have been developed, little attention has been paid to
integration among programs or the resolution of inconveniences
occurring when users use multiple programs.12,13 In order to
respond to their needs, the Garuda Alliance (Garuda Platform,
http://www.garuda-alliance.org/) was formed as a strategic
partnership with software developers. Then, the subsequent
platform that was developed was made available to researchers.
The members of this HD Physiology Project have greatly
contributed to the efforts. Now, domestic and foreign universities
as well as research organizations expressed interest in this project.
Approximately 80 programs currently support the Garuda Plat-
form; these programs provide language independent Application
Programming Interface to connect software as gadgets, and
enable seamless integration among such programs intensively
through the Garuda Gateway.
Meanwhile, other teams of the first-axis worked on cutting-edge
methodologies and technologies such as molecular dynamics,
coding, and parallel computing techniques, organic chemistry,
and molecular imaging.
Multilevel systems biology of cardiac electrophysiological activity
(second-axis)
The second-axis focused on the function of a single organ, i.e., the
heart, adopting a middle-out approach14,15 to examine functions
at the molecular or tissue/organ level while investigating relatively
well-known cardiomyocytes. In particular, the investigation of
unique issues related to arrhythmia-associated genetic abnorm-
alities, molecular remodeling, neural control, and cardiac excita-
tion propagation aimed to understand the robustness or failure of
electrical activity in the heart resulting from the vertical
integration of functions evoked at each system level within the
heart.
In order to advance the field of systems biology, we proposed
novel ideas associated with the robustness of electrical activities in
the heart, i.e., compensatory, protective, and prevent mechanisms.
The first example (compensatory mechanism) resulted from
simulations of the excitation conduction in ventricular myofiber
models: electrical function evoked via the intercellular nanos-
tructure between ventricular myocytes prevents conduction
failure when the electrical coupling between myocytes through
gap junctions is markedly reduced by diseases or drugs.16,17 The
second example (protective mechanism) resulted from simula-
tions of the action potential propagation in the two-dimensional
network model of myocardial fibers within the atrioventricular
(AV) node: an anatomical tissue architecture in the AV node can
function to protect against conduction block-mediated arrhyth-
mias.18 The third example (protective mechanism) resulted from
simulations of the scroll-wave reentry in three-dimensional
ventricular slab model: ventricular tissue architecture, including
different types of myocyte and rotated fiber orientation,
can reduce the risk of the development and sustainability of
ventricular tachycardia/fibrillation attributed to the increase in the
transmural dispersion of repolarization.19 The subcellular localiza-
tion of signaling molecules and intra-/intercellular microstructures
between the molecular and cellular levels as well as the tissue
architecture comprising various types of cells among the cellular,
tissue, and organs levels are closely associated with the robustness
of electrical phenomena in the heart as a principle of comple-
mentarity. These theoretical predictions may be an example of the
nature of biological system and help to understand how we
should organize knowledge in multilevel systems biology.
Furthermore, by the comprehensive evaluation with experi-
mental data and simulation analysis, we successfully provided
the following new drug targets and strategies for improving
arrhythmia: (1) gap junction openers for the treatment of
progressive cardiac conduction defects;20 (2) a type 5 adenylyl
cyclase selective inhibitor for the treatment of atrial
fibrillation;21–24 (3) a hERG channel inhibitor with a facilitation
action for protection against triggering activities;25,26 and (4) a
TRPM4 selective inhibitor for the treatment of atrial and
ventricular arrhythmias associated with elevated TRPM4 expres-
sion.27,28 Basically, each example was hypothesized from the
extensive simulation studies with mathematical models of the
etiology of the heart diseases and the pharmacology of drug
candidates, and then evaluated and validated in the animal study.
Of note, the type 5 adenylyl cyclase selective inhibitor is currently
undergoing clinical study, because sufficient efficacy was already
demonstrated in cellular and animal experiments as well as
mathematical simulation studies.
Multilevel systems biology of small molecular dynamics in
circulation (third-axis)
The third-axis focused on the emergence of functions resulting
from the interdependence of multiorgan functions, i.e., the
horizontal integration of biological functions evoked at each
organ level. As individual organs are connected by blood flow, the
description and prediction of changes in the concentrations of
small compounds in blood are the most important aspects for
understanding the behavior of small molecules in each organ and
tissue. From the viewpoint of the homeostasis of small molecules
in the blood, the prototype beta version of whole-body
physiological ADME (multi-compartment or lumped parameter
ODE) models based on existing descriptions of pharmacokinetics
on our platform was implemented; although incomplete, these
models can roughly predict the behavior by in vitro-in vivo
extrapolation and identify unresolved issues by complementing
experimental and computational approaches. PhysioDesigner was
used to model the abstracted organ modules as compartments
within which the concentration of a drug is assumed to be
uniformly equal and connected by circulation—not just in a
mathematical model, but more importantly in a series of models
that are linked across scales to represent organ function—and
incorporate key reaction processes important for the function of
the higher levels from the lower ones (e.g., cellular and molecular
events). Incorporating quantitative data on ADME obtained
in vitro29–32 into the physiological ADME model enabled the
reproduction and prediction of the pharmacokinetics observed in
humans in vivo even when drug–drug interactions occur.33
Modularity supported by PHML is adequate for this strategy and
is not supported by other commercial or open-source software.
As PBPK models require many parameters to reproduce
physiological functions, efficient parameter estimation methods
are essential. We successfully applied a recently developed
algorithm called the Cluster Newton Method (CNM) to estimate
a feasible solution space.34 After improving the original CNM
algorithm to maintain parameter diversities, a feasible solution
space was successfully estimated for parameters in the PBPK
HD Physiology Project in Japan
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model of irinotecan (a chemotherapy agent) to predict large inter-
individual variability in drug responses in cancer patients.
Application of the CNM achieved a feasible solution space by
solving inverse problems of a system containing ODEsThis method
may provide reliable insights into other complicated phenomena
that have several parameters to estimate with limited information.
This method is also helpful for designing prospective studies
further investigating phenomena of interest.
As was the case in studies from the second-axis, those from the
third-axis demonstrated the common concept in multilevel
systems biology: the architecture of organs and tissue, including
spatial tissue microstructure, is crucial for recapturing physiologi-
cal phenomena at the individual level. For example, although
several models for the prediction of local pharmacokinetics in the
gastrointestinal tract have been reported, these models are
incapable of analyzing nonlinear pharmacokinetics because they
do not consider drug concentration in enterocytes, in which
metabolism and transport processes among others are actually
nonlinear. We successfully released a new local pharmacokinetic
model of gastrointestinal absorption, the translocation model,
which uses an anatomically relevant, minimally segmented
structure and explains linear and nonlinear intestinal drug
absorption, metabolism, and transport.35 The translocation model
is relatively simple compared to existing models, making it useful
for the prediction of drug absorption during drug development in
the future. Furthermore, the physiological model would more
accurately analyze various events occurring during the ADME
process by adjusting the model’s structure and parameters as
necessary. We also developed a technique for the absolute
quantitative determination of the expression levels of multiple
proteins, such as transporters and enzymes participating in
medicine excretion and xenobiotic detoxification. Our compre-
hensive circulation model that incorporates the translocation
model and the quantitative information obtained can accurately
provide key information to determine the exposure of the drug to
therapeutic targets in the body, while each model that works
independently enables us to deepen our understanding about the
detailed mechanism of PBPK.
Target occupancy profiles for drugs were calculated from their
mean unbound plasma concentrations and reported dissociation
constant (Kd) values. Therefore, a computer simulation can identify
the effects of drugs and highlight ways to maximize their clinical
benefit and minimize side effects.36 This study focused on
sunitinib, a multi-kinase inhibitor with antitumor and anti-
angiogenic activities that is known to cause numerous adverse
reactions.37 In silico simulations indicated that unwanted drug-
mediated inhibition of phosphorylase kinase might cause
oxidative stress in body tissues. We emphasize that this finding
was subsequently confirmed in human tests.37 Studies in mice
also suggest that combining antioxidant therapy with kinase
inhibitors could be used to reduce adverse side effects.37 Thus, our
systems toxicological approach successfully predicted the mole-
cular mechanisms underlying clinically adverse reactions asso-
ciated with a given drug.
Summary of research achievements of this project
Scientific achievements of this project have been published in
more than 800 papers in 5 years. Fifty-nine research papers of
those are achieved by the joint research between researchers in
this project with this project as the first opportunity (by June
2015). This obviously indicates that the core team of project
managers had exercised great care in the communication and
cooperation between researchers from the different axes, and
that it has gone well. Without help from the researchers from the
different axes, the first-axis researcher had never developed
the research platform with current versatility and usability, while
the researcher working on cardiology or small molecular dynamics
in the second and third-axes had never tested his/her hypothesis
about the functional processes emerged from the complex
multilevel biological systems without helps in other axes. Models
successfully guided experiments and clinical treatment strategy,
and predicted a previously unknown mechanism about several
issues in cardiology and small molecular dynamics.
INFLUENCES
Although the HD Physiology Project was completed in 2016, it has
already had a tremendous impact. Efforts have already been made
to make this platform the global standard. For example, Flint K3, a
cloud-based simulation service, was introduced on the NeCTAR
research cloud and opened to all Australian researchers, and
PhysioDesigner and Flint were introduced on the International
Neuroinformatics Coordinating Facility Japan-node Simulation
platform operated by Riken NIJC. In Singapore, the Garuda
Platform was implemented on the super computer introduced
to the A*STAR Computing Resource Center. In addition, there
several pharmaceutical companies and cosmetics manufacturers
have made inquiries about PhysioDesigner/Flint and the Garuda
Platform. The platform’s use and applications are also spreading to
the field of education. PhysioDesigner and Flint have been
introduced for educational purposes to some national universities
in Japan, such as Osaka University and the Kyushu Institute of
Technology. That is how use of the platform developed is
spreading not only to academia, but also to industry and
education.
Moreover, this project has certainly promoted research activities
related to systems biology and the physiome in Japan, and has
ensured further development in this field. Researchers involved in
this project, especially young researchers, have been encouraged
and recruited to positions where they can utilize their abilities to
the fullest. Several research projects derived from the HD
Physiology Project have been conducted, including projects
related to translational research that extrapolate the findings of
the original investigations and achievements of the HD Physiology
Project to the broad fields of laboratory, clinical, and public health
research.
SELF-EVALUATION AND OUTSIDE EVALUATION OF THE
MANAGEMENT OF HD PHYSIOLOGY
After the experience in this HD Physiology Project, we affirm that a
consortium approach is quite effective in promoting multilevel
systems biology and other emerging multidisciplinary research
areas. Project leaders need to consider the organic linkage of
researchers, and the framework of the organization of the
consortium is one of the most important factors. The three-axes
framework of HD Physiology Project had worked very well, the
researcher in each axis develops his/her research in a synergistic
or cooperative manner in the project and more easily in the
subdivided axis. Our survey indicates that one subgroup had been
collaborating on the subproject with two other subgroups on
average (about 80 collaborative subprojects/40 subgroups),
and 59 of the research papers have been reported from the
collaboration research, as mentioned previously. The size of this
project was not too large to manage, but a little smaller size would
be better to focus on the most important issues and to clarify the
sharing of responsibility and processing execution by persons
responsible for each action. The HD Physiology Project made a
commitment to promote multilevel integrative systems biology
and physiome research, especially in Japan, and had embodied
that for 5 years. Achievement of the project was evaluated by an
outside reviewing team appointed by MEXT Japan and is
appreciated very highly in the aspects of scientific achievements,
young researcher development, world-wide leadership, and
project management.
HD Physiology Project in Japan
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CONCLUSION
The HD Physiology Project aimed to expand the research field
of systems biology to multilevel systems biology in Japan. The
software platform that was developed as a result was launched
into a public research network, promoting the sustained
advancement of the integrative life sciences. The fruits of the
HD Physiology Project represents are set to demonstrate the
impact and utility of software and tools, and have also addressed
many challenges in the fields of cardiology and pharmacokinetics.
The tools and protocols that were developed can be applied to
other systems and are helping to drive the application of
modeling and simulations to medicine. As such, this project has
contributed significantly to the development of a new paradigm
in biology and medicine. Moreover, qualitative logics and dynamic
modeling have the potential to revolutionize medicine by spurring
“predictive medicine” based on a vast body of knowledge; in
particular, they can be applied to drug discovery and therapy,
including personalized medicine, novel diagnostic and surgical
procedures, medical device design and use, and education
and training. Furthermore, the researchers who participated in
this project will lead decision-making regarding a framework to
enable interoperability between the different simulation software
systems for physiology and clinical purposes. This will be
important for future international initiatives for the intellectual
processes concerning human life and welfare.
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